Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Development of Transdermal Ondansetron Hydrochloride for the Treatment of Chemotherapy-Induced Nausea and Vomiting

Rajan Rajabalaya , Ding Siok Chen, Sheba Rani Nakka David

Department of Pharmaceutical Technology, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia;

For correspondence:- Rajan Rajabalaya Email: rajanrajabalaya@imu.edu.my Tel:+60327317210

Received: 6 July 2012 Accepted: 17 April 2013 Published: 12 June 2013

Citation: Rajabalaya R, Chen DS, David SR. Development of Transdermal Ondansetron Hydrochloride for the Treatment of Chemotherapy-Induced Nausea and Vomiting. Trop J Pharm Res 2013; 12(3):279-285 doi: 10.4314/tjpr.v12i3.1

© 2013 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To to develop and evaluate matrix-type ondansetron hydrochloride (OS) transdermal patch for the treatment of chemotherapy-induced nausea and vomiting.

Methods: Transdermal patches were prepared by solvent casting method using ethyl cellulose and polyvinyl pyrrolidone as matrix materials, and dibutyl phthalate and dibutyl sebacate as plasticizers. The formulations were evaluated for patch thickness, tensile strength, moisture content, water absorption capacity and drug content. In vitro drug release and permeation of the patches were determined using a Franz diffusion cell.

Results: the tensile strength of all the formulations was in the range from 6.09 to 9.85 Mpa indicating that the [patches were strong. Maximum drug release in 8 h for dibutyl phthalate DBP and dibutyl sebacate DBS patches was 38.9 (DB6) and 53.4 % (DS3), respectively, which are significantly (p < 0.01) higher than the lowest values of 17.8 (for DB1) and 35.0 % for (DS5), respectively. Drug release rate was 1.89 and 3.93 μg/h/cm², respectively with DS2 and DB2 showing the highest permeation rate of 5.39 μg/h/cm². Patches containing DBP followed Higuchi release model while patches formulated with DBS followed first order release kinetics.

Conclusion: Ondansetron matrix-type transdermal patches formulated with suitable amounts of chemical enhancers for better patient compliance are feasible.

Keywords: Ondansetron hydrochloride, Chemical enhancers, Plasticizers, Dibutyl phthalate, Dibutyl sebacate, Permeation, Patch